14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:APTX
Delisted

Aptinyx Inc Stock Price (Quote)

NASDAQ Stock Exchange > Healthcare > Biotechnology
Open Broker Account
$0.0960
+0 (+0%)
At Close: Mar 28, 2024
Forecast Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0960 $0.0960 Thursday, 28th Mar 2024 APTX stock ended at $0.0960. During the day the stock fluctuated 0% from a day low at $0.0960 to a day high of $0.0960.
90 days $0.0900 $0.0960
52 weeks $0.0310 $0.148

Historical Aptinyx Inc prices

Date Open High Low Close Volume
Mar 28, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 27, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 26, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 25, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 22, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 21, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 20, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 19, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 18, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 15, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 14, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 13, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 12, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 11, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 08, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 07, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 06, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 05, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 04, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Mar 01, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Feb 29, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Feb 28, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Feb 27, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Feb 26, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Feb 23, 2024 $0.0960 $0.0960 $0.0960 $0.0960 0
Click to get the best stock tips daily for free!

About Aptinyx Inc

Aptinyx Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also deve... APTX Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT